Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tuesday, April 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals, Inc. announced inducement grants under NASDAQ Listing Rule 5635(c)(4) to support employee recruitment. The company awarded 8,925 restricted stock units to six non-executive employees, with a vesting schedule of four years. This initiative is part of Rigel's strategy to attract talent and enhance employee retention. Rigel, focused on developing therapies for hematologic disorders and cancer, continues to emphasize its commitment to its workforce.
Price reaction · baseline $27.36 (2026-04-06 close) · hit after-hours · clean, no other RIGL news in the window
day 0 close
+5%
day 1 · peak
+8.7%
day 3
+6.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel granted 8,925 restricted stock units to bolster staff retention.
  • Inducement grants are aimed at attracting and retaining key talent.
  • The plan reflects Rigel's commitment to employee compensation and growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 8,925 restricted stock units to six non-executive employees vesting over four years with 25% of the grant vesting each year.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.

Frequently Asked Questions

What awards did Rigel Pharmaceuticals announce on April 7, 2026?

Rigel Pharmaceuticals announced grants of 8,925 restricted stock units.

Who received the awards from Rigel Pharmaceuticals?

The awards were granted to six non-executive employees.

What is the vesting schedule for the stock units?

The stock units vest over four years, with 25% vested each year.

What is the focus of Rigel Pharmaceuticals?

Rigel is dedicated to developing therapies for hematologic disorders and cancer.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals NASDAQ restricted stock units employee recruitment biotechnology
Last updated: Apr 7, 2026

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →